Introduction
============

Since the report of a plasmid-mediated colistin resistance (PMCR) mechanism, designated MCR-1, in *Escherichia coli* and *Klebsiella pneumoniae* isolated from animals, food and humans in China, further reports exposed the global dissemination of *mcr*-type gene in various bacterial species isolated from a wide range of different sources ([@B6]). In Portugal, PMCR has also been detected in a wide range of different sources and species, including humans, food-producing animals and meat, and in the environment ([@B5]; [@B9]; [@B13]; [@B14]; [@B16]; [@B23]; [@B17]). Noteworthy, are the recent report of two cases presumably associated with the travel of patients from Portugal, one involving animals: a patient repatriated to France after hospitalization for 2 months in Portugal, in 2015 ([@B3]), and a New York state patient returning from Portugal in 2016 after staying on a farm with chickens and pigs ([@B11]).

More worrisome is the presence of *mcr* genes in *Enterobacteriaceae* carrying other resistance determinants namely, extended-spectrum β-lactamases (ESBL)- and/or carbapenemase-encoding genes. Since the first report of co-localization of *mcr-1* and ESBL- in 2016 in bovines in France, an increase encoding genes in the proportion of *mcr-1* genes among ESBL-producing *E. coli* in animals has been noticed, suggesting that the use of extended-spectrum cephalosporins may have simultaneously favored the spread of *mcr-1* ([@B12]). Here we describe the first detection of a novel *mcr* variant, hereafter-named *mcr-1.9*, identified in a commensal *E. coli* LV23529 isolated from a swine cecum sample collected at a slaughter, in Portugal.

Materials and Methods {#s1}
=====================

Bacterial Isolate
-----------------

*Escherichia coli* LV23529 was isolated in 2015 from a swine cecum sample collected at a Portuguese slaughter, during an evaluation study of commensal *E. coli* recovered from swine samples for antimicrobial susceptibility testing.

Antimicrobial Susceptibility Testing
------------------------------------

Minimum inhibitory concentrations (MICs) were determined by microdilution method as previously described ([@B16]). In order to assess decreased susceptibility of the strain, interpretation of the results was done according to the epidemiological cut-off values recommended by the European Committee on Antimicrobial Susceptibility Testing (EUCAST^[1](#fn01){ref-type="fn"}^).

Screening and Characterization of PMCR- and ESBL-Resistance Mechanisms
----------------------------------------------------------------------

### Molecular Detection of *mcr-1* and *bla*~ESBL~-Encoding Genes

Following phenotypic characteristics, PMCR- and ESBL-resistance mechanisms were searched and identified by molecular methods, as previously described ([@B16]).

### Transfer Experiments

Conjugation experiments were performed using sodium azide-resistant *E. coli* J53 as a recipient strain. Transconjugants were selected on McConkey agar supplemented with sodium azide (150 mg/L) and either cefotaxime (2 mg/L) or colistin (2 mg/L). Plasmid DNA was extracted from *E. coli* LV23529 using a NucleoBond Xtra Plus kit (Macherey-Nagel), and transformed into *E. coli* TOP10 OneShot chemically competent cells (Invitrogen), accordingly to manufacture's protocol. *E. coli* transformants were selected on MacConkey agar supplemented with 2 mg/L of colistin. PCR for *bla*~CTX-M-8~ or *mcr-1*-type and MICs of recipients and transformants were determined as mentioned above.

### Genetic Context of *mcr-1.9* Gene

Colistin-resistant *E. coli* LV23529 was genotypically characterized by whole-genome sequencing (WGS), as previously described ([@B16]). Sequence reads were trimmed and filtered according to quality criteria, and de novo assembled into contigs by means of CLC Genomics Workbench 10.0 (Qiagen). The assembled contigs were analyzed and studied for the presence of antibiotic resistance, virulence genes and plasmid replicon types, serotype, multi-locus sequence type (ST) and *fim*-type, using bioinformatics tools^[2](#fn02){ref-type="fn"}^. The NCBI prokaryotic genome automatic annotation pipeline (PGAAP) was used for annotation.

Plasmid sequencing was also performed on a MiSeq Illumina platform using 150 bp paired-end reads, after plasmid DNA extraction from TLV23529 (*mcr-1.9*) using a NucleoBond Xtra Plus kit (Macherey-Nagel), and quantification using Qubit 1.0 Fluorometer (Invitrogen), as previously described ([@B16]). Sequence reads were trimmed and filtered according to quality criteria, and mapped against *E. coli* ATCC 25922 genome (NZ_CP009073). Unmapped reads (80.2%/total reads) were then used for plasmids structure construction by mapping assembly based on the genetic organization of the closest plasmid sequences obtained by BLASTn; this was followed by contig neighbor's prediction from assembly information using CLC Genomics Workbench 10.0 (Qiagen). NCBI Microbial genomes BLAST analysis tool^[3](#fn03){ref-type="fn"}^ was used to search for plasmid sequences. Plasmid alignments and ORF representations were also done using EasyFig v. 2.2.3 ([@B21]).

### Genomic Epidemiological Analysis

BacWGSTdb database was used for genotyping and source tracking bacterial pathogen ([@B19]).

### Nucleotide Sequence Accession Number

The pLV23529-MCR-1.9 and pLV23529-CTX-M-8 nucleotide sequences from this study were submitted to the NCBI GenBank Database with accession numbers [KY964067](KY964067) and [KY964068](KY964068), respectively. The new *mcr-1.9* nucleotide sequence was submitted with accession number [KY780959](KY780959).

This Whole Genome Shotgun project has been deposited at DDBJ/ENA/GenBank under the accession SBIH00000000. The version described in this paper is version SBIH01000000.

Results and Discussion
======================

MIC results showed that LV23529 was non-wild-type to third- and fourth-generation cephalosporins (ceftazidime 2 mg/L, cefotaxime 32 mg/L, cefepime 8 mg/L) with synergy with clavulanic acid; this isolate was also non-wild-type to chloramphenicol (\>128 mg/L), sulphamethoxazole (\>1024 mg/L), trimethoprim (\>32 mg/L), tetracycline (\>64 mg/L), and colistin (4 mg/L). LV23529 remained wild-type to carbapenems, fluoroquinolones, aminoglycosides and tigecycline ([Table 1](#T1){ref-type="table"}).

###### 

Phenotypic and genotypic context of CTX-M-8 and MCR-1.9 producing *E. coli* clinical isolate, transformant, transconjugant, and the respective recipient strains.

  Antibiotic                        LV23529^b^   Transformation   Conjugation              
  --------------------------------- ------------ ---------------- ------------- ---------- ---------
  Ampicillin                        \>64         4                8             2          \>64
  Cefoxitine                        4            4                4             4          8
  Ceftazidime                       2            0.5              0.5           ≤0.5       1
  Ceftazidime plus clavulanate^a^   ≤0.125/4     0.5              0.5           ≤0.125/4   ≤0.25/4
  Cefotaxime                        32           ≤0.25            ≤0.25         ≤0.25      2
  Cefotaxime plus clavulanate^a^    ≤0.06/4      0.125            0.125         ≤0.06/4    ≤0.06/4
  Cefepime                          8            0.125            0.125         ≤0.06      2
  Imipenem                          0.25         0.5              0.5           0.25       0.25
  Meropenem                         ≤0.03        0.06             0.06          ≤0.03      ≤0.03
  Ertapenem                         ≤0.015       ≤0.015           ≤0.015        ≤0.015     ≤ 0.015
  Nalidixic acid                    ≤4           ≤4               ≤4            ≤4         ≤4
  Ciprofloxacin                     ≤0.015       ≤0.015           ≤0.015        ≤0.015     ≤0.015
  Chloramphenicol                   \>128        ≤8               ≤8            ≤8         ≤8
  Sulphamethoxazole                 \>1024       ≤8               ≤8            ≤8         ≤8
  Tetracycline                      \>64         ≤2               ≤2            ≤2         ≤2
  Trimethoprim                      \>32         ≤0.25            ≤0.25         ≤0.25      ≤0.25
  Gentamicin                        ≤0.5         ≤0.5             ≤0.5          ≤0.5       ≤0.5
  Colistin                          4            ≤1               2             ≤1         ≤1
  Tigecycline                       ≤0.25        ≤0.25            ≤0.25         ≤0.25      ≤0.25
                                                                                           

MICs in mg/L.
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Molecular characterization of the *E. coli* LV23529 isolate allowed the detection of *bla*~CTX-M-8~ and *mcr-1*-type genes.

Only the transferability of the *bla*~CTX-M-8~ gene was achieved by conjugation, with TcLV23529 (*bla*~CTX-M-8~) exhibiting the ESBL phenotype from LV23529 isolate (cefotaxime 2 mg/L, cefepime 2 mg/L) with synergy with clavulanic acid, and wild-type to colistin (≤1 mg/L) ([Table 1](#T1){ref-type="table"}). Although conjugation assays for *mcr-1*-type were negative, the colistin resistance determinant could be transferred to *E. coli* TOP10 competent cells; transformant TLV23529 (*mcr-1*-type) showed the respective resistance to colistin (4 mg/L) ([Table 1](#T1){ref-type="table"}).

The WGS assembly of *E. coli* LV23529 yielded 193 contigs (average 143.7-fold coverage), which together comprised 5,122,415bp, showing a GC content of 50.7%. The largest contig was 320,931 bp long; the N50 statistic, which stands for the minimum contig length of at least 50% of the contigs, was 113,197 bp. The average length of the obtained contigs was 26,541 bp. Overall, the genome sequence comprised 5,124 putative genes, among which 5,037 consisted of protein encoding sequences.

The WGS analysis showed that *E. coli* LV23529 belongs to serotype O8:H19, usually associated with porcine *stx*~2e~-producing *E. coli* ([@B27]; [@B2]), and to MLST (Achtman scheme) ST201 \[clonal complex 469 (CC469)\] and to the FimH-type determinant *fimH32*. This ST201 was encountered worldwide mainly in isolates collected from livestock samples (*Escherichia*/*Shigella* Enterobase database, [@B1]). Three virulence factors were detected: *astA* (heat-stable enterotoxin 1), *lpfA* (long polar fimbriae), and *gad*-type (glutamate decarboxylase).

Further bioinformatics analysis of *E. coli* LV23529 isolate revealed acquired-genes conferring resistance to β-lactams (*bla*~CTX-M-8~ and *bla*~TEM-1~), aminoglycosides (*aadA1* and *aadA2*), phenicol (*cmlA1-type* and *floR*-type), sulphamethoxazole (*sul3*), tetracycline \[*tet(A)*-type and *tet(M)*-type\], trimethoprim (*dfrA12*), and colistin (*mcr-1-type*), justifying the phenotype noticed. Additionally, several unknown mutations in the *ampC* (promoter region), *parC*, 16S *rrsB*, 16S *rrsC*, 23S and *pmrB* chromosomal genes were detected, the last gene being described as the primary mechanism for the development of chromosomally encoded resistance to polymyxins ([@B18]).

The named *mcr-1.9*, differed from *mcr-1* by one-point mutation (T1238C), leading to Val413Ala substitution. The MCR-1 protein contains a transmembrane domain and a phosphoethanolamine (PEA) transferase domain with 8α, 12β, and 12η units ([@B10]). The amino acid substitution of MCR-1.9 occurred in the region between η7 e η8 of the PEA transferase domain, which have been found not to influence the function of MCR-1 ([@B10]).

The *mcr-1.9* genetic context was characterized by an IS*26* element upstream of the *mcr-pap2* element and by the absence of IS*Apl1* ([Figure 1](#F1){ref-type="fig"}), which is in accordance with other studies about *mcr-1* gene ([@B24]; [@B22]). The *mcr-1*.9 gene can be mobilized within an IS*Apl1*-flanked composite transposon (Tn*6330*), although many sequences have been identified without IS*Apl1* or with just a single copy ([@B20]). Indeed, it has been described that initially IS*Apl1* was presumably involved in the transposition of the *mcr-1* cassette and then was lost, contributing for the stability of *mcr* gene on IncX4 plasmids ([@B22]; [@B20]).

![Linear comparison of IncX4-pLV23529-MCR-1.9 with the top six *mcr-1*-harboring plasmids showing the highest identities (\>99.9%, E-value 0.0), in different *E. coli* isolates. Boxed arrows represent the position and transcriptional direction of ORFs. Gray vertical blocks indicate the shared similarity regions according to TBLASTX identity. Genes associated with pilus and plasmid transfer are colored yellow, antibiotic resistance genes are colored red, mobile genetic elements are colored pink, and other genes are colored gray (hypothetical proteins) or blue (other).](fmicb-10-00367-g001){#F1}

The PMCR-encoding gene was found in an IncX4 plasmid (pLV23529-MCR-1.9), showing highest identities (\>99.9%) with six IncX4-type *mcr-1*-harboring plasmids identified worldwide, in unrelated *E. coli* isolates, mainly collected from human patients ([Figure 2](#F2){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). Indeed, all belonged to different MLST, which might suggest a resistance plasmid dissemination across strains (plasmid outbreak) rather than clonal transmission of MCR-1-type-producing strains. Furthermore, no *E. coli* LV23529 closely related isolates were detected among those currently deposited in the public database BacWGSTdb ([@B19]), which reinforce the importance of the horizontal gene transfer in this study.

![Schematic representation of the genetic environment of *mcr-1.9* in comparison with other *mcr-1*-type representative environments. Boxed arrows represent the position and transcriptional direction of ORFs. Genes are not drawn to scale. Genes associated with pilus and plasmid transfer are colored yellow, antibiotic resistance genes are in red, mobile genetic elements in pink, plasmid maintenance and stability genes in violet, plasmid replication associated genes are in light blue, and other genes are colored gray (hypothetical proteins) or blue (other).](fmicb-10-00367-g002){#F2}

###### 

Comparison of IncX4-pLV23529-MCR-1.9 with the top six *mcr-1*-harboring plasmids showing the highest identities (\>99.9%, E-value 0.0), in different *E. coli* isolates.

  IncX4-type Plasmid (bp)     *E. coli* strain (MLST^a^)   Source/Country/Year                 Identity (%)   Mismatches/gap opens (No. of nucleotides)   Query alignment overlap (%)   pLV23529-MCR-1.9 Alignment overlap (%)   Plasmid GenBank Acc. No.
  --------------------------- ---------------------------- ----------------------------------- -------------- ------------------------------------------- ----------------------------- ---------------------------------------- --------------------------
  **pMCRpoa** (33,511)        3431F (ST744)                Human patient/Brazil/2014           99.98          **15/1**                                    99.4                          100.0                                    CM007714
  **pl4EC007a** (35,098)      14Ec007 (ST301)              Human patient/China/2014            99.98          **15/1**                                    94.9                          100.0                                    CP024132
  **pMCR-1-NY** (33,304)      MDR56 (ST117)                Human patient /United States/2015   99.97          **19/1**                                    100.0                         100.0                                    CP019908
  **pICBEC72Hmcr** (33,304)   ICBEC72H (ST101)             Human patient/Brazil/2016           99.95          **17/0**                                    100.0                         100.0                                    CP015977
  **pl4EC033b** (33,301)      14EC033 (ST2064)             Human patient/China/2014            99.92          **16/3**                                    100.0                         100.0                                    CP024149
  **pICBEC7Pmcr** (34,992)    ICBEC7P (ST10)               Magellanic penguins/Brazil/2013     99.92          **16/3**                                    95.2                          100.0                                    CPO17246
                                                                                                                                                                                                                                 

a

MLST accordingly with Warwick scheme (

http://mlst.warwick.ac.uk/mlst/dbs/Ecoli

).

Like pLV23529-MCR-1.9, the six plasmids ([Table 2](#T2){ref-type="table"}) doesn't have the IS*Apl1* element. Hence, similarities may suggest that the one-point mutation (T1238C) in *mcr-1.9* occurred on the X4 plasmid, since mobilization of *mcr-1* occurs as part of a composite transposon (Tn*6330*) and that structures lacking the downstream IS*Apl1* are not capable of mobilization ([@B20]). The IS*26* upstream of the *mcr-pap2* element is flanked by an 8bp direct repeat ([Figure 3A](#F3){ref-type="fig"}), indicating that its insertion wouldn't seems to be related to the *mcr-1.9* context, justifying the differences found with other IncX4 *mcr-1*-harboring plasmids. IncX4 plasmid has been widely implicated in the spread of MCR-1 gene in Europe ([@B6]). In Portugal, this plasmid type is circulating among diverse hosts (humans, pigs, poultry), being responsible for hospital-based outbreak caused by MCR-1 plus KPC-3-producing *K. pneumoniae* ([@B17]), as well as for the diffusion of this PMCR at the farm level ([@B14]). Indeed, IncX4 plasmids seem to be efficiently transferred at different temperatures and different lack-of-fitness burdens among bacterial hosts, which may facilitate the transfer of *mcr-type* among *Enterobacteriaceae* ([@B15]; [@B26]). The pLV23529-MCR-1.9 plasmid backbone contains all the core genes common to IncX plasmids involved in segregation, stability, replication, and conjugative transfer of the plasmid ([Figure 3A](#F3){ref-type="fig"}), namely the IncX-type pilus synthesis operon (*pilX1*-*pilX11*). However, pLV23529-MCR-1.9 was mobilizable, but not self-transmissible. Of note, we found a one-point mutation (G64T), leading to Asp22Tyr substitution, in the PilX1, a peptidoglycan hydrolase involved in T-DNA plasmid transfer. This mutation might explain why the attempts to conjugate *mcr-1.9* from *E. coli* LV23529 were unsuccessful ([@B7]).

![Schematic maps of pLV23529-MCR-1.9 **(A)** and pLV23529-CTX-M-8 **(B)**. Genes are denoted by arrows and colored based on gene function classification.](fmicb-10-00367-g003){#F3}

Further plasmid analysis revealed the presence of two other plasmids: IncF \[F2:A-:B-\], IncR and the colicinogenic IncI1-ST113-carrying the *bla*~CTX-M-8~ (pLV23529-CTX-M-8, [Figure 3B](#F3){ref-type="fig"}). Of note, the *mcr-1.9*-positive isolate, co-harboring *bla*~CTX-M-8~ and *bla*~TEM-1~ genes, is here reported for the first time in an *E. coli* isolate of animal origin. In fact, *bla*~CTX-M-8~ gene is rarely detected in Europe in isolates of animal origin ([@B4]), but in humans seems to be emerging ([@B8]). Indeed, a recent phylogenetic study suggested an increasing trend of co-existence and transmission of *bla*~CTX-M~ and *mcr-1* in both clinical medicine and veterinary medicine ([@B25]).

In conclusion, the presence of PMCR-encoding genes, such as MCR-1.9, in food-producing animals represents a potential threat to humans, as it is located in mobile genetic elements that have the potential to spread horizontally. As mentioned, in Portugal, PMCR is an emerging problem and its international spread is a worrying reality ([@B3]; [@B11]).
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